Madrigal Pharmaceuticals Gets Price Target Bumps By Analysts Following Successful NASH Study

Madrigal Pharmaceuticals Inc MDGL announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom.

Madrigal Pharmaceuticals shares jumped 268.1% to close at $234.83 on Monday and gained 4.4% to trade at $245.26 on Tuesday.

These analysts made changes to their price targets on Madrigal Pharmaceuticals after the company released Phase 3 trial results.

  • SVB Leerink raised the price target on Madrigal Pharmaceuticals from $145 to $315. SVB Leerink analyst Mike Kratky maintained an Outperform rating on the stock.
  • JMP Securities boosted the price target from $182 to $312. JMP Securities analyst Jonathan Wolleben maintained the stock with a Market Outperform.
  • Goldman Sachs raised the price target on the stock from $178 to $375. Goldman Sachs analyst Andrea Tan maintained the stock with a Buy.
  • Oppenheimer raised the price target on Madrigal Pharmaceuticals from $170 to $250. Oppenheimer analyst Jay Olson maintained the stock with an Outperform.
  • HC Wainwright & Co. raised the price target from $170 to $225. HC Wainwright & Co. analyst Ed Arce maintained Madrigal Pharmaceuticals with a Buy.


Check out this: Intrepid Potash, Braskem And More: 4 Cheapest Stocks In The Materials Sector

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: NewsPrice TargetMarketsAnalyst RatingsTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!